Technical Analysis for PLXP - PLx Pharma Inc.

Grade Last Price % Change Price Change
grade A 5.6 -2.10% -0.12
PLXP closed down 2.1 percent on Monday, May 20, 2019, on 3.93 times normal volume. It was able to find support at its 50 day moving average. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical PLXP trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Stochastic Reached Overbought Strength 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Overbought Stochastic Strength 0.00%

Older signals for PLXP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.
Biopharmaceutical Drugs Organic Compounds Cardiovascular Disease Analgesics Hepatotoxins Carboxylic Acids Ibuprofen
Is PLXP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 10 PLx Pharma's (PLXP) CEO Natasha Giordano on Q1 2019 Results - Earnings Call Transcript
May 10 Edited Transcript of PLXP earnings conference call or presentation 10-May-19 12:30pm GMT
May 10 The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
May 10 PLx Pharma reports Q1 results
May 10 PLx Pharma Inc. Reports First Quarter 2019 Results
May 3 PLx Pharma (PLXP) Expected to Beat Earnings Estimates: Should You Buy?
May 2 PLx Pharma Inc. to Discuss 2019 First Quarter Financial Results on May 10, 2019 Conference Call
Apr 1 Biotech Winners, Losers In Q1
Mar 25 PLx Pharma files for $75M mixed shelf
Mar 9 Edited Transcript of PLXP earnings conference call or presentation 8-Mar-19 1:30pm GMT
See more PLXP news...
Indicators
Indicator Value
52 Week High 6.4392
52 Week Low 1.0
Average Volume 11,849
200-Day Moving Average 4.3181
50-Day Moving Average 5.5016
20-Day Moving Average 5.5266
10-Day Moving Average 5.5425
Average True Range 0.3689
ADX 16.8
+DI 15.5501
-DI 17.2966
Chandelier Exit (Long, 3 ATRs ) 4.7633
Chandelier Exit (Short, 3 ATRs ) 6.1167
Upper Bollinger Band 5.8331
Lower Bollinger Band 5.2201
Percent B (%b) 0.62
BandWidth 11.091811
MACD Line 0.051
MACD Signal Line 0.0385
MACD Histogram 0.0125
Fundamentals Value
Market Cap 48.65 Million
Num Shares 8.69 Million
EPS -1.03
Price-to-Earnings (P/E) Ratio -5.44
Price-to-Sales 196.43
Price-to-Book 5.02
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.36
Resistance 3 (R3) 6.30 5.97 6.24
Resistance 2 (R2) 5.97 5.78 6.01 6.19
Resistance 1 (R1) 5.79 5.66 5.88 5.85 6.15
Pivot Point 5.46 5.46 5.51 5.50 5.46
Support 1 (S1) 5.28 5.27 5.37 5.35 5.05
Support 2 (S2) 4.95 5.15 4.99 5.01
Support 3 (S3) 4.77 4.95 4.96
Support 4 (S4) 4.84